Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 10,000 | |||
5 mg | 在庫あり | ¥ 16,000 | |||
10 mg | 在庫あり | ¥ 22,500 | |||
25 mg | 在庫あり | ¥ 43,500 | |||
50 mg | 在庫あり | ¥ 80,000 | |||
100 mg | 在庫あり | ¥ 137,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 25,000 |
説明 | Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively. |
ターゲット&IC50 | Axl:<1 nM (cell free), c-Met:6.7 nM (cell free), VEGFR2:1.9 nM (cell free) |
In vitro | In cell-based functional assays, Ningetinib inhibits VEGF and HGF-stimulated HUVEC proliferation and microvascular angiogenesis in rat aortic rings with IC50 values of 6.3 and 8.6 nM, respectively. |
In vivo | In the orthotopic U87MG human glioblastoma xenograft model, Ningetinib prolongs the median survival time and yields a significant increase in life-span value (ILS=32%) at an oral dose of 20 mg/kg/day (dosed 21 days) versus the vehicle-treated group. When single dosed orally (3 mg/kg) to U87MG tumor-bearing nude mice, Ningetinib potently inhibits the phosphorylation of c-Met and its downstream signaling kinases AKT and ERK1/2 for up to 6 hours in tumor tissues. |
分子量 | 728.79 |
分子式 | C38H37FN4O8S |
CAS No. | 1394820-77-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 8 mg/mL (10.98 mM), Sonication and heating are recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ningetinib Tosylate 1394820-77-9 Angiogenesis Tyrosine Kinase/Adaptors VEGFR c-Met/HGFR TAM Receptor Inhibitor Tyro3 inhibit Axl Vascular endothelial growth factor receptor Ningetinib Mer inhibitor